Closure of patent foramen ovale in “cryptogenic” stroke: Has the story come to an end?

Abstract

Contrasting with three randomized trials that failed to show any superiority of patent foramen ovale closure over antithrombotic therapy, two trials recently reported lower rates of stroke recurrence among patients assigned to patent foramen ovale closure than among those assigned to antiplatelet therapy. In addition, one of the initially negative trials concluded in favor of patent foramen ovale closure after an extended follow-up period. A better selection of patients, the use of reference treatment groups that included patients who received antiplatelet therapy alone (rather than antiplatelet drugs or oral anticoagulants, according to physician preference), and a longer follow-up of patients, may explain the divergent findings across studies. Procedural complications were reported in 1.5% to 5.9% of the patients, none of which led to permanent disability or death. Patent foramen ovale closure was associated with an increased risk of new-onset atrial fibrillation in several studies and of venous thromboembolism in one study.

Keywords

stroke cryptogenic patent foramen ovale atrial septal aneurysm transcatheter closure antiplatelet therapy oral anticoagulants

Get full access to this article

View all access options for this article.

References

Lechat

Mas

Lascault

et al.

Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148–1152.

Alsheikh-Ali

Thaler

Kent

. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009; 40: 2349–2355.

Furlan

Reisman

Massaro

et al.

Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991–999.

Carroll

Saver

Thaler

et al.

Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092–1100.

Meier

Kalesan

Mattle

et al.

Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083–91.

Mas

J-L

Derumeaux

Guillon

et al.

Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377: 1011–1021.

Søndergaard

Kasner

Rhodes

et al.

Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033–1042.

Saver

Carroll

Thaler

et al.

Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 1022–1032.

Cabanes

Mas

Cohen

et al.

Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age: a study using transesophageal echocardiography. Stroke 1993; 24: 1865–1873.

10.

Mas

J-L

Arquizan

Lamy

et al.

Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740–1746.

11.

Goel

Tuzcu

Shishehbor

et al.

Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 2009; 103: 124–129.

12.

Kent

Dahabreh

Ruthazer

et al.

Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J 2015; 36: 2381–2389.